1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
US6277991A · kind A · utility
16Cited by
4References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 1999 |
| Grant date | Aug 21, 2001 |
| Priority date | — |
| Expiry date | May 13, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2054
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the use of triaza-spiro compounds of formula ##STR1## wherein PA1 R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, z and n are defined in the specification, for the treatment of migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.